These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30355191)

  • 1. Identification of Corticospinal Tract Lesion for Predicting Outcome in Small Perfusion Stroke.
    Zhou Y; Zhang R; Yan S; Zhang M; Chen Z; Hu H; Zhang M; Bivard A; Lin L; Parsons MW; Lou M
    Stroke; 2018 Nov; 49(11):2683-2691. PubMed ID: 30355191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Too good to treat? ischemic stroke patients with small computed tomography perfusion lesions may not benefit from thrombolysis.
    Bivard A; Lou M; Levi CR; Krishnamurthy V; Cheng X; Aviv RI; McElduff P; Lin L; Kleinig T; O'Brien B; Butcher K; Jingfen Z; Jannes J; Dong Q; Parsons MW
    Ann Neurol; 2016 Aug; 80(2):286-93. PubMed ID: 27352245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of perfusion lesion in corticospinal tract on response to reperfusion.
    Zhou Y; Zhang R; Zhang S; Yan S; Wang Z; Campbell BCV; Liebeskind DS; Lou M
    Eur Radiol; 2017 Dec; 27(12):5280-5289. PubMed ID: 28540481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
    Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
    Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C;
    N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
    Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment.
    Ospel JM; Menon BK; Demchuk AM; Almekhlafi MA; Kashani N; Mayank A; Fainardi E; Rubiera M; Khaw A; Shankar JJ; Dowlatshahi D; Puig J; Sohn SI; Ahn SH; Poppe A; Calleja A; Hill MD; Goyal M
    Stroke; 2020 Nov; 51(11):3232-3240. PubMed ID: 33070714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
    Li W; Lin L; Zhang M; Wu Y; Liu C; Li X; Huang S; Liang C; Wang Y; Chen J; Feng W
    Stroke; 2016 Oct; 47(10):2649-51. PubMed ID: 27608821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
    Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Dewey HM; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Ang T; Miteff F; Levi CR; Rodrigues E; Zhao H; Salvaris P; Garcia-Esperon C; Bailey P; Rice H; de Villiers L; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Wong AA; Muller C; Coulthard A; Mitchell K; Clouston J; Mahady K; Field D; Ma H; Phan TG; Chong W; Chandra RV; Slater LA; Krause M; Harrington TJ; Faulder KC; Steinfort BS; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
    N Engl J Med; 2018 Apr; 378(17):1573-1582. PubMed ID: 29694815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exclusion of Isolated Cortical Swelling Can Increase Efficacy of Baseline Alberta Stroke Program Early CT Score in the Prediction of Prognosis in Acute Ischemic Stroke Patients Treated with Thrombolysis.
    Naito T; Takeuchi S; Arai N
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2754-8. PubMed ID: 26460245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
    Cappellari M; Moretto G; Micheletti N; Donato F; Tomelleri G; Gulli G; Carletti M; Squintani GM; Zanoni T; Ottaviani S; Romito S; Tommasi G; Musso AM; Deotto L; Gambina G; Zimatore DS; Bovi P
    J Thromb Thrombolysis; 2014 May; 37(4):549-56. PubMed ID: 23943338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
    de Ridder I; den Hertog H; van Gemert M; Dippel D; van der Worp B;
    Cerebrovasc Dis; 2013; 35(1):60-3. PubMed ID: 23428998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke.
    Kim DH; Lee DS; Nah HW; Cha JK
    BMC Neurol; 2018 Mar; 18(1):30. PubMed ID: 29544461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the DRAGON score in an elderly Spanish population: prediction of stroke prognosis after IV thrombolysis.
    Giralt-Steinhauer E; Rodríguez-Campello A; Cuadrado-Godia E; Ois Á; Jiménez-Conde J; Soriano-Tárraga C; Roquer J
    Cerebrovasc Dis; 2013; 36(2):110-4. PubMed ID: 24029547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of admission serum glucose on the clinical prognosis of patients with acute ischemic stroke receiving alteplase intravenous thrombolysis.
    Huang P; Yi X
    Int J Immunopathol Pharmacol; 2023; 37():3946320231204597. PubMed ID: 37771034
    [No Abstract]   [Full Text] [Related]  

  • 19. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
    Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
    Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation.
    Tu HT; Campbell BC; Christensen S; Desmond PM; De Silva DA; Parsons MW; Churilov L; Lansberg MG; Mlynash M; Olivot JM; Straka M; Bammer R; Albers GW; Donnan GA; Davis SM;
    Int J Stroke; 2015 Jun; 10(4):534-40. PubMed ID: 23489996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.